UCARTCS1A is a SLAMF7 targeted allogeneic (donor-derived) CAR T-cell therapy being developed for multiple myeloma patients.
| SparkCures ID | 338 |
|---|---|
| Developed By | Cellectis S.A. |
| Generic Name | UCARTCS1A |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
July 07, 2020
Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its MELANI-01 trial.